Evidence map›Paper›PMID 40430961›Full record

ArticlePharmaceutics2025

Preparation and Characterization of Ternary Complexes to Improve the Solubility and Dissolution Performance of a Proteolysis-Targeting Chimera Drug.

Heng Zhang, Hengqian Wu, Lili Wang, Laura Machín Galarza, Chuanyu Wu, Mingzhong Li, Zhengping Wang, Erpeng Zhou, Jun Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Heng ZhangSchool of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China.
Hengqian WuInstitute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252000, China.
Lili WangInstitute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252000, China.
Laura Machín GalarzaInstitute of Pharmacy and Foods, University of Havana, Havana 17100, Cuba.ORCID 0000-0002-0708-6789
Chuanyu WuSchool of Chemistry and Chemical Engineering, University of Surrey, Guildford GU2 7XH, UK.ORCID 0000-0003-2721-5231
Mingzhong LiSchool of Pharmacy, De Montfort University, Leicester LE1 9BH, UK.ORCID 0000-0002-9532-9049
Zhengping WangInstitute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252000, China.
Erpeng ZhouCollege of Chemical Engineering, Shijiazhuang University, Hebei International Joint Research Center for Biopharmaceutical, Shijiazhuang 050035, China.
Jun HanSchool of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China.

Funding

National Science and Technology Major Project 2017ZX09201-003Open Project of Shandong Collaborative Innovation Center for Antibody Drugs CICAD1828Science Foundation of Liaocheng University 318052420Taishan Industry Leading Talents of China tscx202312172
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

dissolution enhancementproteolysis targeting chimeras (PROTACs)sulfobutyl ether-β-cyclodextrinternary complexvitamin E-TPGS

Identifiers

PMID40430961
PMCPMC12115006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.